Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: Two randomized trials

International Journal of STD and AIDS

Volumn 13, Issue 1, 2002, Pages 12-21

  Conant, M A ^a   Schacker, T W ^b   Murphy, R L ^c   Gold, J ^d   Crutchfield, L T ^e   Crooks, R J ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e GLAXOSMITHKLINE   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Herpes simplex virus; HIV; Recurrent genital herpes; Valaciclovir

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VALACICLOVIR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GENITAL HERPES; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; TREATMENT OUTCOME;

ACYCLOVIR; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HERPES GENITALIS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SIMPLEXVIRUS; TREATMENT OUTCOME; VALINE;

EID: 18244396615     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462021924550     Document Type: Article

References (38)

1. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions
2. Genital herpes simplex infections in patients with the acquired immunodeficiency syndrome
3. Prevalence and incidence herpesvirus infections among homosexually active men
4. Prevalence and correlates of herpes simplex infections. The Population-based AIDS in Multiethnic Neighborhoods Study
5. Prevalence of antibodies to human herpesviruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection
6. Clinical and serologic features of herpes simplex virus infection in patients with AIDS
7. Management of herpesvirus infections (CMV, HSV, VZV)
8. The association between genital ulcer disease and acquisition of HIV infection in homosexual men
9. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men
10. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men
11. Sexual transmission of HIV and the epidemiology of other sexually transmitted diseases
12. Long-term suppression of recurrent genital herpes with acyclovir
13. Prophylactic oral acyclovir in recurrent genital herpes
14. Suppression of frequently recurring genital herpes: A placebo-controlled double-blind trial of oral acyclovir
15. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes
16. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation
17. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers
18. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans
19. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease
20. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
21. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
22. Scintillation proximity radioimmunoassay for the measurement of acyclovir
23. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir
24. A comparative study of the in vitro and in vivo antiviral activities of acyclovir and penciclovir
25. Regression models and life tables
26. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: Results of an international, multicenter, double-blind, randomized clinical trial
27. Valaciclovir versus aciclovir in patient-initiated treatment of recurrent genital herpes: A randomised, double blind clinical trial
28. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis
29. Valaciclovir for the suppression of recurrent genital HSV infections: A large scale dose range finding study
30. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes
31. Acyclovir-resistant herpes simplex virus in HIV-infected individuals: Results from an ongoing US surveillance study
32. Long-term safety of valaciclovir for suppression of herpes simplex virus infections
33. Manifestations resembling thrombotic microangiopathy in patients with advanced HIV disease in a cytomegalovirus prophylaxis trial (ACTG 204)
34. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection
35. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus type 1 (HIV-1) infection
36. Human immunodeficiency virus infection and thrombotic microangiopathy